drugset / Trial / NCT06511570

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

NCT06511570

Phase 1 Completed 28 enrolled Acumen Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Timeline

Start
2024-06-25
Primary completion
2024-09-17
Completion
2024-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject sabirnetug Monoclonal antibody Intravenous
Background rHuPH20 Protein / enzyme biologic Subcutaneous

Indications